CD19 and B-cell non-Hodgkin lymphoma: One hundred fifty‐four R/R B‐cell lymphoma patients who received CAR‐T therapy targeting CD19, still alive and in follow‐up, were enrolled in this study and presented in Figure 1, the median duration between CAR‐T infusion and study enrollment was 1183 days (2–2168 days).